- Home
- DBD vs AUPH Comparison
DBD vs AUPH Comparison
Compare DBD & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DBD | AUPH |
|---|---|---|
| Founded | 1859 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DBD | AUPH |
|---|---|---|
| Price | $63.25 | $16.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $98.33 | $17.86 |
| AVG Volume (30 Days) | 215.0K | ★ 757.9K |
| Earning Date | 10-28-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 677.27 | ★ 5075.00 |
| EPS | ★ 0.58 | 0.53 |
| Revenue | ★ $3,805,700,000.00 | $283,055,000.00 |
| Revenue This Year | $2.62 | $15.83 |
| Revenue Next Year | $3.05 | $21.30 |
| P/E Ratio | $108.90 | ★ $31.38 |
| Revenue Growth | 1.46 | ★ 20.38 |
| 52 Week Low | $54.48 | $10.92 |
| 52 Week High | $92.09 | $19.25 |
Technical Indicators
Market Signals| Indicator | DBD | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 56.66 |
| Support Level | $62.92 | $15.65 |
| Resistance Level | $67.28 | $17.02 |
| Average True Range (ATR) | 1.81 | 0.40 |
| MACD | 0.45 | 0.01 |
| Stochastic Oscillator | 54.38 | 74.67 |
Price Performance
Historical ComparisonAbout DBD Diebold Nixdorf Incorporated
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.